Steris (STE) Tops Q1 EPS by 7c, Revenues Beat

Steris (NYSE: STE) reported Q1 EPS of $1.03, $0.07 better than the analyst estimate of $0.96. Revenue for the quarter came in at $668.9 million versus the consensus estimate of $635.98 million.

“We are pleased with our overall performance during such a challenging time,” said Walt Rosebrough, President and Chief Executive Officer of STERIS. “Our results this quarter reflect the benefits of STERIS’s balanced and diversified business model as well as certain non-recurring items. As anticipated, our Healthcare segment was the most impacted by the reduction of deferrable procedures. Our Life Sciences segment continued its strong performance due to increased demand from pharma Customers focused on vaccines and biologics. Due to the continuing uncertainty we are not providing guidance for fiscal 2021.”

For earnings history and earnings-related data on Steris (STE) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Avis Budget Group reaches $650M settlement with Pentwater Capital
• Ennis (EBF) Reports In-Line Q1 EPS